| Autor: |
V Aswathy, Sasidharan Pillai, Chandra, Kotha Rohith, Jyothikrishna, Pakkath, Arun, Kanniappan Parthasarathy |
| Zdroj: |
Pharmacogenomics; January 2022, Vol. 23 Issue: 3 p195-206, 12p |
| Abstrakt: |
Clopidogrel is a prodrug chiefly metabolized by the hepatic isoenzyme CYP2C19 to its active metabolite that inhibits the platelet aggregation. It has been proven in many populations that the genetic polymorphism of CYP2C19has influence on the pharmacokinetic and or pharmacodynamics of this drug and resulting in high inter-individual variability in the treatment outcomes. As CYP2C19genetic polymorphism is highly prevalent among the Asian population, the influence of the same on the pharmacokinetics and; thereby, the pharmacodynamics of clopidogrel needs more attention. Using the pharmacogenetic information for drug therapy could help overcome these issues and to optimize the dosage regimen of clopidogrel, this review advocates the precision medicine approach for reducing the clopidogrel resistance and adverse cardiovascular events. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
